AstraZeneca, Novartis Continued Divestment Sprees In 2018, While Peers Joined The Action
Executive Summary
While leading large pharma with seven out-licensing or divestiture deals apiece during 2018, AstraZeneca and Novartis each slowed their pace somewhat. But several peer companies followed suit, as there were 31 such deals among the 20 largest biopharma firms last year.